William Blair maintains Outperform on Sarepta Therapeutics (NASDAQ: SRPT).Analyst Tim Lugo defends the stock and would be a buyer noting ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE